Mittoval (Alfuzosin Hydrochloride)

Alfuzosin, the active ingredient in Mittoval, is an Alpha-1 adrenergic blocker presented as a tablet for oral use. It treats benign prostatic hyperplasia in adult men, improving urinary flow and reducing symptoms. GNH USA supplies Mittoval as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Alfuzosin is used to manage conditions related to prostate enlargement and lower urinary tract obstruction. - Benign prostatic hyperplasia: improves urinary flow and reduces nocturia, hesitancy and weak stream. - Lower urinary tract symptoms due to BPH: alleviates urgency, frequency and incomplete bladder emptying. - Bladder outlet obstruction from enlarged prostate: relaxes smooth muscle to facilitate voiding.

Adverse reactions may occur with alfuzosin therapy.

Common Side Effects: - Dizziness: light‑headed sensation, especially on standing. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness or reduced energy. - Nasal congestion: stuffy or runny nose. - Retrograde ejaculation: semen may flow backward. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure, may cause fainting. - Syncope: sudden loss of consciousness. - Priapism: prolonged, painful erection. - Anaphylactic reaction: severe allergy with swelling, rash, breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm. - Liver injury: elevated enzymes or jaundice.

Before initiating alfuzosin, consider the following safety measures. - Renal impairment: assess kidney function and adjust if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant alpha‑blockers: avoid additive hypotensive effects. - History of orthostatic hypotension: monitor blood pressure regularly. - Drug interactions: review all concurrent medications for potential interactions. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Alfuzosin may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase alfuzosin plasma concentrations. - Other alpha‑1 blockers (e.g., tamsulosin, prazosin): additive risk of severe hypotension. - Nitrates (e.g., nitroglycerin): can cause profound blood pressure lowering.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce alfuzosin effectiveness. - Antihypertensives (e.g., ACE inhibitors, ARBs): may enhance blood pressure‑lowering effect. - Diuretics: increase risk of orthostatic hypotension, especially in the elderly.